Cargando…

Co-stimulatory tumor necrosis factor ligands as adjuvants for the development of subunit-based anticancer vaccines

Tumor-associated antigen (TAA) subunit-based vaccines constitute promising tools for the anticancer immunotherapy. Given the weak antigenic nature of most TAAs, however, the efficacy of TAA-based vaccines requires adjuvants exerting potent immunostimulatory functions. Co-stimulatory members of the t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shirwan, Haval, Sharma, Rajesh K., Srivastava, Abhishek K., Yolcu, Esma S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654576/ https://www.ncbi.nlm.nih.gov/pubmed/23734306 http://dx.doi.org/10.4161/onci.23440

Ejemplares similares

CD4(+) T Cells Play a Critical Role in the Generation of Primary and Memory Antitumor Immune Responses Elicited by SA-4-1BBL and TAA-Based Vaccines in Mouse Tumor Models
por: Sharma, Rajesh K., et al.
Publicado: (2013)

Fas/Fas-Ligand Interaction As a Mechanism of Immune Homeostasis and β-Cell Cytotoxicity: Enforcement Rather Than Neutralization for Treatment of Type 1 Diabetes
por: Yolcu, Esma S., et al.
Publicado: (2017)

Prime-Boost Vaccination with SA-4-1BBL Costimulatory Molecule and Survivin Eradicates Lung Carcinoma in CD8(+) T and NK Cell Dependent Manner
por: Srivastava, Abhishek K., et al.
Publicado: (2012)

SA-4-1BBL Costimulation Inhibits Conversion of Conventional CD4(+) T Cells into CD4(+)FoxP3(+) T Regulatory Cells by Production of IFN-γ
por: Madireddi, Shravan, et al.
Publicado: (2012)

Correction: SA-4-1BBL Costimulation Inhibits Conversion of Conventional CD4(+) T Cells into CD4(+)FoxP3(+) T Regulatory Cells by Production of IFN-γ
por: Madireddi, Shravan, et al.
Publicado: (2012)

Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy
por: Sharma, Rajesh Kumar, et al.
Publicado: (2010)

Mechanisms of Tolerance Induction by Hematopoietic Chimerism: The Immune Perspective
por: Yolcu, Esma S., et al.
Publicado: (2017)

4-1BB Signaling in Conventional T Cells Drives IL-2 Production That Overcomes CD4(+)CD25(+)FoxP3(+) T Regulatory Cell Suppression
por: Barsoumian, Hampartsoum B., et al.
Publicado: (2016)

Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?
por: Hsu, Andy, et al.
Publicado: (2012)

A co-stimulatory trap set by myeloid leukemia cells
por: Esendagli, Gunes
Publicado: (2013)

A modified surgical procedure using minimally invasive ileocolic vein perfusion in a mouse intrahepatic islet transplant model
por: Zhang, Lei, et al.
Publicado: (2022)

Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?
por: Swarbrick, Alexander, et al.
Publicado: (2013)

Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody
por: Houot, Roch, et al.
Publicado: (2012)

Zoledronate-pulsed dendritic cell-based anticancer vaccines
por: Kamigaki, Takashi, et al.
Publicado: (2013)

Targeting MDSCs enhance therapeutic vaccination responses against lung cancer
por: Srivastava, Minu K., et al.
Publicado: (2012)

Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy
por: Wei, Huafeng, et al.
Publicado: (2014)

Boosting anticancer vaccines: Too much of a good thing?
por: Ricupito, Alessia, et al.
Publicado: (2013)

Continuous 4–1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy
por: Chacon, Jessica Ann, et al.
Publicado: (2013)

NKT cell adjuvants in therapeutic vaccines against hematological cancers
por: Mattarollo, Stephen R., et al.
Publicado: (2013)

Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard
por: Hailemichael, Yared, et al.
Publicado: (2013)

High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies
por: Binder, David C, et al.
Publicado: (2013)

Engineering donor lymphocytes with Fas ligand protein effectively prevents acute graft-versus-host disease
por: Shrestha, Pradeep, et al.
Publicado: (2023)

Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination
por: Dosset, Magalie, et al.
Publicado: (2013)

Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines
por: García-Vallejo, Juan J., et al.
Publicado: (2013)

Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings
por: Gungor, Bilgi, et al.
Publicado: (2014)

The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer
por: Demaria, Sandra, et al.
Publicado: (2013)

Membrane-bound KIT ligand-targeting DNA vaccination inhibits mammary tumor growth
por: Dentelli, Patrizia, et al.
Publicado: (2014)

Modulating gut immunity and neoplasia with oral cytokine adjuvants
por: Ozbilge, Hatice, et al.
Publicado: (2015)

Cellular senescence enhances adaptive anticancer immunosurveillance
por: Marin, Ines, et al.
Publicado: (2022)

A mitochondrial checkpoint to adaptive anticancer immunity
por: Kepp, Oliver, et al.
Publicado: (2023)

Multifunctional γδ T cells and their receptors for targeted anticancer immunotherapy
por: Scheper, Wouter, et al.
Publicado: (2013)

Parvoviruses-tools to fine-tune anticancer immune responses
por: Grekova, Svitlana P., et al.
Publicado: (2012)

The anticancer effects of HDAC inhibitors require the immune system
por: West, Alison C, et al.
Publicado: (2014)

Effector and Naturally Occurring Regulatory T Cells Display No Abnormalities in Activation Induced Cell Death in NOD Mice
por: Kaminitz, Ayelet, et al.
Publicado: (2011)

MAGE-A3-specific anticancer immunotherapy in the clinical practice
por: Brichard, Vincent G, et al.
Publicado: (2013)

ATM activation mediates anticancer immunosurveillance by natural killer and T cells
por: Tang, Melissa LF, et al.
Publicado: (2013)

Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy
por: Ma, Yuting, et al.
Publicado: (2014)

An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells
por: Senovilla, Laura, et al.
Publicado: (2013)

Empowering scFv with effector cell functions for improved anticancer therapeutics
por: Zhang, Hongtao
Publicado: (2013)

Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy
por: Schreibelt, Gerty, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_j3mo2erldfc5gm52ni09egs6n4